Acadia Pharma (ACAD) Q2 Revs of $115.2M; Tops EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street closes lower as oil prices jump, indexes notch monthly gains
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
- Energy stocks rally as fresh U.S.-Iran attacks drive oil prices higher
- BofA turns S&P 500 signals from red to yellow: What to buy now
Acadia Pharmaceuticals Reports Second Quarter 2021 Financial Results
August 4, 2021 4:05 PM EDT- 2Q21 net sales of $115.2 million, a 5% increase over 2Q20
- Fiscal year 2021 revenue guidance reduced to $480 to $515 million
- Type A meeting held with FDA regarding DRP; Acadia will continue discussion with FDA in another meeting later this year
SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the second quarter ended June 30, 2021.
NUPLAZID performed well in the second quarter of 2021, highlighted by our ability to drive growth while still... More
